To evaluate hepatitis A (HAV) endemicity in six countries via systematic review of published literature. The countries represent varying seroprevalence (different stages of the HAV epidemiologic transition), stages of vaccine consideration, and face different circumstances that may affect vaccine adoption. METHODS: Articles published from 1990 to October 2011 were identified through a number of article search engines, including PubMed ® . Search terms were "Hepatitis A" and [Country]. Reference lists of identified articles were reviewed for relevant articles published prior to 1990. A supplementary Internet search identified additional information not indexed in the reviewed search engines. Articles were excluded if they focused on the biological mechanisms of hepatitis A, were non-human studies, vaccine trial results, case studies or opinion pieces. RESULTS: A total of 797 articles were identified. After exclusions, the number of articles reviewed were: Chile, 33; India, 80; Mexico, 25; Russia, 38; South Korea, 75; and Taiwan, 65. India is still considered to have high HAV endemicity, while Chile and Mexico are intermediate, and Korea, Russia, and Taiwan are low. The timeframe of available data differed greatly by country and often region/city within a country, with some regions only having data as recent as five (in Mexico, Taiwan) or ten (in Chile, India, Russia) years ago. Data supporting the HAV epidemiologic transition varied by country, and it was often unclear at which point the country transitioned to a lower endemicity category, if at all. Hepatitis A incidence data were sparse for some countries, and recent outbreaks were reported in Korea and Taiwan. CONCLUSIONS: Data gaps, including determination of the HAV epidemiologic transition, exist to some extent in all the countries studied. Filling these data gaps to enhance knowledge of the burden of HAV will assist countries in decision-making regarding vaccine adoption. 
OBJECTIVES:
Pharmaceutical spending in Brazil represents approximately 11% of its total Gross Domestic Product (GDP). Sales of generics represented 17.2% of the pharmacy sector by value and 21.3% by volume in 2010, and are expected to grow at a higher rate than the overall pharmacy market. This study looks at how the increase in generics use, along with reference price controls, may impact access to newly approved Community Acquired Pneumonia (CAP) drugs. METHODS: An array of published data such as pricing process, current policies, sector-specific research articles contributed towards a framework to understand the key factors affecting access to CAPs drugs, were gathered. The data then informed a telephone survey of national and regional health care stakeholders (N=5). RESULTS: Findings show that in Brazil: 1) New CAP products are placed in 1 of 2 product categories based on comparisons to comparator agents; 2) Category I products are considered to be better than the comparator and can charge a premium price; 3) The price cannot exceed the lowest price of 9 reference countries, which are Australia, Canada, Spain, USA, France, Greece, Italy, New Zealand and Portugal; 4) Category II products do not demonstrate a benefit over the comparator and the price is based on a cost-minimization analysis; and 5) There are no national guidelines for treating CAP. CONCLUSIONS: Drugs used to treat CAP are compared to comparator agents based on clinical efficacy and overall patient benefit. This will determine placement in a product category that will drive pricing. Pharmaceutical companies developing new antibiotics to treat CAP must 1) consider launch sequence/timing in reference price countries; 2) assess the impact of price based on product category placement; 3) demonstrate cost-effectiveness of the drug; and 4) determine whether a new product will provide a benefit over comparator agents. OBJECTIVES: Attendance at biannual medical visits has been proposed as a minimum U.S. standard for adequate engagement in human immunodeficiency virus (HIV) care. The U.S. National HIV Surveillance System collects dates of HIV laboratory tests but not medical visits, the current metric for determining if a patient is engaged in medical care. Using data from the HIV Outpatient Study (HOPS), we analyzed how reported laboratory data correlated with actual engagement in care. METHODS: The HOPS is an open prospective study of HIVinfected patients receiving outpatient care. The dataset included dates for laboratory measurements and medical encounters. We included patients with at least one HIV laboratory test and one medical visit during 2010-2011. An HIV laboratory test was associated with a medical visit if it occurred within 3 weeks of the visit. We assessed the predictive value of HIV laboratory tests as a proxy for adequate engagement in clinical care, defined as having had ≥2 HIV laboratory tests within 1 year where the tests were performed ≥90 days apart. RESULTS: A total of 10,301 HIV laboratory tests were recorded from among 2,895 patients. Most (75%) laboratory tests were measured on the same day as a clinical visit; 90% were within ±3 weeks. The prevalence of adequate engagement in clinical care in HOPS based on medical visits was 89%. Using HIV laboratory tests to measure engagement had sensitivity of 85%, specificity of 87%, and positive and negative predictive values of 98% and 42%. Of the 21.4% of persons classified as not engaged in care by the proxy measure, 58% were actually engaged. CONCLUSIONS: Using ≥2 documented HIV laboratory tests measured ≥90 days apart reliably classified persons as engaged in care. However, more than half of persons not meeting the proxy definition were misclassified as not adequately engaged in care. 
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PIN107 ANTIFUNGAL TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH A BLOOD CULTURE POSITIVE FOR CANDIDA AND WITH SEPSIS OR CRITICAL ILLNESS
OBJECTIVES:
Timely initiation of antifungal therapy in septic or critically ill (CrILL) patients with candidemia is crucial, and real-world treatment and outcomes data in such patients are limited. We examined treatment patterns and outcomes for septic/CrILL inpatients with candidemia. METHODS: This retrospective study of electronic health record data from 7/2005-3/2012 used Cerner's Health Facts. Adult inpatients with ≥1 blood culture positive for any species of Candidaand sepsis/CrILL were studied. CrILL was defined as ≥1 organ system dysfunction plus intensive care unit exposure. Timing of initial antifungal therapy relative to the index blood culture draw (BCx), length-of-stay following first antifungal order (AF-LOS), mortality, and measures of resource utilization were explored using descriptive statistics. Chi-square was used for proportional, and t-test for continuous data comparisons. RESULTS: Of 1,288 candidemia patients with sepsis/CrILL, 266 initiated antifungal therapy prior to BCx, 150 within 24h of BCx, 590 after 24h, and 282 received no antifungal therapy. The mortality rates were 39.9%, 30.7%, 29.7%, and 51.1%, respectively. (P<0.001). Initial antifungal therapies in those treated ≤24h of BCx were: fluconazole in 54.0%, echinocandin in 39.3%, other azoles in 3.3%, and amphotericin B in 3.3%. In patients treated within 24h after BCx with fluconazole (n=81) or echinocandin (n=59), occurrence of bacteremia was high (71% vs. 75%); echinocandin patients had a higher mean number of organ system dysfunctions than fluconazole patients (1.8 vs. 1.5, P=0.04). In the ≤24h treated groups, AF-LOS (fluconazole 20.8, echinocandin 22.1 days; P=0.63) and mortality (fluconazole 25.9%, echinocandin 32.2%; P=0.42) was similar, as were total charges (approximately US$76,000). CONCLUSIONS: A large proportion of inpatients with candidemia and sepsis/CrILL failed to receive antifungal therapy within 24h of the first positive BCx, with an adverse mortality effect. Nonetheless, patients treated within 24h have high mortality and resource utilization.
PIN108 TREATMENT PATTERNS IN PEDIATRIC ANTIBIOTIC FORMULATIONS: AN ANALYSIS OF THE RAMQ DATABASE
Lachaine J 1 , Beauchemin C 1 , Lapierre ME 1 , Snow LA 2 1 University of Montreal, Montreal, QC, Canada, 2 Abbott, QC, Canada OBJECTIVES: In clinical practice, the taste of liquid pediatric antibiotics may contribute to treatment acceptance and compliance. The purpose of this study was to analyze treatment patterns and persistence with liquid pediatric antibiotics, in a real life setting, using the RAMQ database. METHODS: Selected patients were < than 20 years old and were covered by the Quebec provincial drug reimbursement program (RAMQ). They were prescribed a liquid pediatric antibiotic (branded or generic formulation) during the period from July 2008 to April 2011 at least once. The analyses evaluated patients and treatment characteristics and patterns in terms of short-term (30 days or less) and longterm (> than 30 days) repeated use. RESULTS: Data were available for a sample of 67,727 patients who used an antibiotic of interest. The average age of the study population was 4.7 years (SD=3.5) and 89.9% were < than 10 years old. The proportion of boys versus girls was similar (51.2% versus 48.8%, respectively). Amoxicillin trihydrate and macrolides, clarithromycin and azithromycin were most often used (49.3% and 33.0%, respectively). About 55.4% of children received more than one antibiotic during the study period. Among children who received a second antibiotic, about 22.5% required it within 30 days following treatment initiation. In the short-term, the need for a second antibiotic was more frequent when cephalosporin was the initial treatment. In the long-term, when the initial treatment was amoxicillin or a macrolide, subsequent antibiotics were more likely to be the same as the first antibiotic. CONCLUSIONS: Many children will require more than one antibiotic treatment during their childhood. Several factors may contribute to short-term acceptance and compliance of the initial antibiotic, one of which may be taste. The better the acceptance and compliance to the initial antibiotic, the more likely the same antibiotic will be used for subsequent treatments.
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